Mylan To Appeal Lorazepam, Clorazepate Antitrust Decision Awarding $35.9 Million In Damages
This article was originally published in The Pink Sheet Daily
Executive Summary
In the last of pending antitrust cases related to lorazepam and clorazepate monopoly, D.C. district court orders Mylan to pay $35.9 million to health insurers.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.